{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:44:06Z","timestamp":1790628246114,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Horizon Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40262-021-01003-3","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T02:02:36Z","timestamp":1616724156000},"page":"1029-1040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease"],"prefix":"10.1007","volume":"60","author":[{"given":"Yan","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Sile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"16","key":"1003_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Hegedus L. Graves\u2019 disease. N Engl J Med. 2016;375(16):1552\u201365. https:\/\/doi.org\/10.1056\/NEJMra1510030.","journal-title":"N Engl J Med."},{"issue":"12","key":"1003_CR2","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348\u201354. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348.","journal-title":"J Immunol."},{"issue":"8","key":"1003_CR3","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"RS Douglas","year":"2008","unstructured":"Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, et al. B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181(8):5768\u201374. https:\/\/doi.org\/10.4049\/jimmunol.181.8.5768.","journal-title":"J Immunol."},{"issue":"5","key":"1003_CR4","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","volume":"178","author":"RS Douglas","year":"2007","unstructured":"Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178(5):3281\u20137. https:\/\/doi.org\/10.4049\/jimmunol.178.5.3281.","journal-title":"J Immunol."},{"issue":"6","key":"1003_CR5","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol. 2008;181(6):4397\u2013405. https:\/\/doi.org\/10.4049\/jimmunol.181.6.4397.","journal-title":"J Immunol."},{"issue":"1","key":"1003_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019;40(1):236\u201367. https:\/\/doi.org\/10.1210\/er.2018-00066.","journal-title":"Endocr Rev."},{"issue":"3","key":"1003_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/BF03345273","volume":"27","author":"TJ Smith","year":"2004","unstructured":"Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest. 2004;27(3):246\u201353. https:\/\/doi.org\/10.1007\/BF03345273.","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"1003_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1210\/en.2019-00055","volume":"160","author":"CC Krieger","year":"2019","unstructured":"Krieger CC, Boutin A, Jang D, Morgan SJ, Banga JP, Kahaly GJ, et al. Arrestin-beta-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk. Endocrinology. 2019;160(6):1468\u201379. https:\/\/doi.org\/10.1210\/en.2019-00055.","journal-title":"Endocrinology"},{"issue":"18","key":"1003_CR9","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med."},{"issue":"4","key":"1003_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med."},{"key":"1003_CR11","unstructured":"Tepezza [prescribing information]. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761143s000lbl.pdf. Accessed 20 Feb 2021."},{"issue":"8","key":"1003_CR12","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","volume":"16","author":"R Kurzrock","year":"2010","unstructured":"Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16(8):2458\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3220.","journal-title":"Clin Cancer Res."},{"key":"1003_CR13","doi-asserted-by":"crossref","unstructured":"Rodon JPA, Stein M, Tolcher A, Ng C, Dias M, Kurman C, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol. 2007;25(18 Suppl. 3590).","DOI":"10.1200\/jco.2007.25.18_suppl.3590"},{"issue":"11","key":"1003_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/11535970-000000000-00000","volume":"49","author":"BB Yang","year":"2010","unstructured":"Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet. 2010;49(11):729\u201340. https:\/\/doi.org\/10.2165\/11535970-000000000-00000.","journal-title":"Clin Pharmacokinet."},{"key":"1003_CR15","unstructured":"Beal SL, Boeckmann AJ, Sheiner LB. NONMEM user\u2019s guide, Part I-VII. San Francisco (CA): University of California at San Francisco; 1988. 1992."},{"issue":"1","key":"1003_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron."},{"issue":"2","key":"1003_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J."},{"key":"1003_CR18","unstructured":"Harling K, Uekcert S, Hooker A. NPC\/VPC userguide and technical description. PsN 3.4.2. http:\/\/psn.sourceforge.net\/pdfdocs\/npc_vpc_userguide.pdf. Accessed 2013."},{"issue":"6","key":"1003_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","volume":"37","author":"EI Ette","year":"1997","unstructured":"Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486\u201395. https:\/\/doi.org\/10.1002\/j.1552-4604.1997.tb04326.x.","journal-title":"J Clin Pharmacol."},{"key":"1003_CR20","unstructured":"Bootstrap user guide. 2011."},{"issue":"2","key":"1003_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/17425255.2012.643868","volume":"8","author":"R Deng","year":"2012","unstructured":"Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 2012;8(2):141\u201360. https:\/\/doi.org\/10.1517\/17425255.2012.643868.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"9","key":"1003_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388. https:\/\/doi.org\/10.1002\/psp4.12224.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"10","key":"1003_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359. https:\/\/doi.org\/10.2165\/11535960-000000000-00000.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"1003_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","volume":"72","author":"DE Mager","year":"2006","unstructured":"Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72(1):1\u201310. https:\/\/doi.org\/10.1016\/j.bcp.2005.12.041.","journal-title":"Biochem Pharmacol."},{"key":"1003_CR25","doi-asserted-by":"publisher","first-page":"b560","DOI":"10.1136\/bmj.b560","volume":"338","author":"P Perros","year":"2009","unstructured":"Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ. 2009;338:b560.","journal-title":"BMJ"},{"issue":"Suppl. 1","key":"1003_CR26","first-page":"A559","volume":"4","author":"GJST Kahaly","year":"2020","unstructured":"Kahaly GJ, Smith TJ, Holt RJ, Sile S, Douglas RS. Effect of teprotumumab on proptosis reduction across various demographic sub-groups (abstract). J Endo Soc. 2020;4(Suppl. 1):A559\u201360.","journal-title":"J Endo Soc."},{"key":"1003_CR27","unstructured":"Scientific T. Protein storage and stability (tech tip #43)."},{"key":"1003_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","volume":"51","author":"H Zhou","year":"2011","unstructured":"Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359\u201372. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100510.","journal-title":"Annu Rev Pharmacol Toxicol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01003-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01003-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01003-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T03:41:57Z","timestamp":1628048517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01003-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01003-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"10 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study NCT00400361 was funded by Hoffman La Roche; studies NCT01868997\u00a0and NCT03461211 and the conduct of these analyses were funded by Horizon Therapeutics plc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yuying Gao and Fengyan Xu received consulting fees from Horizon Therapeutics; Yan Xin, Nivedita Bhatt, Jason Chamberlain, Saba Sile, Suzy Hammel, Robert J. Holt, Thompson, and Srini Ramanathan are employed by and own stocks in Horizon Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interest"}},{"value":"The trials were approved by institutional review boards of participating institutions and performed in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data will not be provided.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}